Abiopharma

Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA forLUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

Ovid Therapeutics Inc. - Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

The Joint Corp. Announces $5 Million Stock Repurchase Program

IDEXX Announces Launch of the Catalyst® Cortisol Test

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea